Get the Stockscreener App
4.89
5.39%
0.25
After Hours:
4.98
0.09
+1.84%
Cellectar Biosciences Inc stock is traded at $4.89, with a volume of 65,494.
It is up +5.39% in the last 24 hours and down -3.74% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$4.64
Open:
$4.68
24h Volume:
65,494
Relative Volume:
0.54
Market Cap:
$15.61M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.5046
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
-20.75%
1M Performance:
-3.74%
6M Performance:
+1,651%
1Y Performance:
+130.66%
1-Day Range:
$4.64
$4.98
1-Week Range:
$4.56
$5.59
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.89 | 14.81M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Is Cellectar Biosciences Inc. stock a safe investment in uncertain marketsPortfolio Update Summary & AI Forecasted Stock Moves - newser.com
Is Cellectar Biosciences Inc. stock a bargain at current levelsIndex Update & AI Driven Stock Movement Reports - newser.com
How to track smart money flows in Cellectar Biosciences Inc.Market Movement Recap & High Accuracy Buy Signal Tips - newser.com
Can Cellectar Biosciences Inc. rally from current levelsJuly 2025 Selloffs & Technical Confirmation Trade Alerts - newser.com
Is Cellectar Biosciences Inc. stock a buy in volatile markets2025 Major Catalysts & Fast Gain Stock Tips - newser.com
Using Python tools to backtest Cellectar Biosciences Inc. strategiesIPO Watch & Long-Term Investment Growth Plans - newser.com
How analysts rate Cellectar Biosciences Inc. stock todayWeekly Trend Recap & Consistent Profit Alerts - newser.com
Predicting Cellectar Biosciences Inc. trend using moving averagesSell Signal & Daily Growth Stock Investment Tips - newser.com
Is Cellectar Biosciences Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
What drives Cellectar Biosciences Inc stock priceLow Risk Investment Ideas & Free Record-Breaking Gains - earlytimes.in
Cellectar Biosciences Raises $5.8M Through Warrant Exercise - MSN
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants - Investing.com Canada
Will Cellectar Biosciences Inc. price bounce be sustainable2025 Top Decliners & Daily Profit Focused Screening - newser.com
What technical models suggest about Cellectar Biosciences Inc.’s comebackEntry Point & High Conviction Trade Alerts - newser.com
Understanding Cellectar Biosciences Inc.’s price movementWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Cellectar Biosciences Inc. stock prediction for this weekMarket Rally & Low Drawdown Investment Ideas - newser.com
Custom watchlist performance reports with Cellectar Biosciences Inc.CPI Data & Long-Term Growth Plans - newser.com
Analyzing net buyer seller activity in Cellectar Biosciences Inc.Quarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences (CLRB) Secures $5.8 Million Through Warran - GuruFocus
Cellectar Biosciences raises $5.8 million through warrant exercise - Investing.com
Cellectar Biosciences enters agreements to raise $5.8M - TipRanks
Cellectar Biosciences raises $5.8 million through warrant exercise By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. enters into agreements to raise $5.8 million - MarketScreener
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million - GlobeNewswire
$5.8M Raised: Cellectar Biosciences Secures Funding via Warrant Exercises to Advance CLR 121125 - Stock Titan
Cellectar’s cancer drug advances toward European approval By Investing.com - Investing.com Nigeria
Cellectar Biosciences Announces European Medicines Agency - GlobeNewswire
Cellectar Biosciences (CLRB) Receives Positive Feedback for EU M - GuruFocus
What margin trends mean for Cellectar Biosciences Inc. stockEarnings Recap Summary & Growth Focused Stock Pick Reports - newser.com
Cellectar’s cancer drug advances toward European approval - Investing.com
Cellectar Biosciences Stock Rises Over EMA's Advise On CMA Filing For Iopofosine I 131 - Nasdaq
Cellectar Biosciences (CLRB) Moves Toward European Market with Potential Cancer Treatment - GuruFocus
Cellectar wins EMA nod to seek conditional approval for iopofosine in rare blood cancer - MarketScreener
Cellectar Biosciences Plans Conditional Marketing Authorization Submission for Iopofosine I 131 as Treatment for Refractory Waldenstrom Macroglobulinemia in Europe by Early 2026 - Quiver Quantitative
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) - The Manila Times
Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm) - MarketScreener
Is Cellectar Biosciences Inc. stock a safe haven assetSell Signal & Long-Term Safe Investment Ideas - newser.com
How Cellectar Biosciences Inc. stock benefits from tech adoption2025 Market Overview & Real-Time Volume Analysis - newser.com
How to forecast Cellectar Biosciences Inc. trends using time series2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Can Cellectar Biosciences Inc. (NV4) stock hold up in economic slowdownTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
What drives Cellectar Biosciences Inc NV4 stock priceIndustrial Stocks Review & Predict Price Movements With AI Precision - earlytimes.in
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cellectar Biosciences Inc Stock (CLRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):